Balance Sheet

v3.26.3
CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2026
Jun. 30, 2025
Current assets    
Cash $ 5,778,586 $ 2,975,150
Accounts receivable, net 97,244 157,515
Inventory, net 265,961 1,152,870
Due from VitaMedica transition 10,766 228,017
Prepaid expenses and other assets 988,542 350,836
Current digital assets at fair value 109,625,166 49,913,655
Purchase price receivable - VitaMedica 0 2,000,000
Total current assets 116,766,265 56,778,043
Property and equipment, net 208,044 2,052,573
Intangible assets, net 86,353 163,113
Goodwill 673,854 848,854
Deferred tax asset 5,948,858 5,948,858
Digital assets at fair value, net of current 55,675,516 56,083,525
Other assets 163,223 192,123
Right-of-use asset, net 598,678 1,739,755
Total noncurrent assets 63,354,526 67,028,801
Total assets 180,120,791 123,806,844
Current liabilities    
Accounts payable 277,644 1,039,370
Accrued compensation 5,277,309 3,470,296
Deferred revenue 4,519 13,155
Accrued liabilities 1,675,521 356,064
Accrued interest 2,349,162 792,449
Acquisition payable 260,652 260,652
Current portion of promissory notes 0 560,000
Short-term treasury debt 57,295,723 20,000,000
Current portion of Cygnet subsidiary notes payable 3,694,721 5,380,910
Current portion of operating lease payable 295,167 691,010
Total current liabilities 71,130,418 32,563,906
Operating lease payable, net of current portion 362,235 1,145,440
Convertible notes payable 162,442,056 0
Total long-term liabilities 162,804,291 1,145,440
Stockholders' equity    
Preferred stock, $0.00001 par value, 10,000,000 shares authorized, and 150,000 shares issued and outstanding 2 2
Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 78,702,358 and 38,270,571 shares issued and outstanding, as of June 30, 2026 and June 30, 2025, respectively 787 383
Additional paid in capital 252,793,813 150,640,935
Accumulated deficit (306,608,520) (60,543,822)
Total stockholders' equity (53,813,918) 90,097,498
Total liabilities and stockholders' equity $ 180,120,791 $ 123,806,844

Source